Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- CSIMC Submits Opinion on Medical Fee Revision Including Views of Both Healthcare Providers and Medical Bill Payers
December 8, 2011
- MHLW Proposes Penalty for Companies that Receive Premium but Refuse Development Requests
December 8, 2011
- Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
- Representatives of Payers, Care Providers Argue Against Freeze on Prices of Essential Drugs
December 8, 2011
- 2010 Survey Shows OB/GYN Doctors, Surgeons Rise in Number
December 7, 2011
- MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
- Orphan Drug Designation Approved for Everolimus, Tafamidis Meglumine
December 6, 2011
- Premium for New Drug Development to Be Continued on Trial Basis: CSIMC Expert Subcommittee
December 6, 2011
- 2010 Survey Shows Rise in Numbers of OB/GYN Doctors, Surgeons
December 6, 2011
- Takeda’s Novel ARB Azilva Recommended for Approval: PAFSC First Committee
December 5, 2011
- CSIMC General Assembly Points Out Some “Reckless” Evaluations on Policy Screening Report
December 5, 2011
- 80% Rule for Combination Drugs Will Be Applied to Injectables, Topical Drugs: MHLW Proposal
December 5, 2011
- MHLW Announces Results of Reexamination for Iressa, Remicade as Category I
December 5, 2011
- PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
December 5, 2011
- Decision on Price Freeze for Medically Essential Drugs to Be Postponed
December 5, 2011
- Expert Subcommittee Approves 60% Pricing Rule for Some New Generics Only
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 3, 2011
- Two New Drugs Including Ranmark from Daiichi Sankyo Recommended at PAFSC's 2nd Committee
December 2, 2011
- SS Council Committees Approve Basic Plan on FY2012 Medical Fee Revision
December 2, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…